Advances in beta cell differentiation have propelled cell therapies for diabetes into the clinic; this Review outlines the lessons learned from early-phase trials and discusses the clinical, manufacturing and regulatory challenges that must now be overcome.
- Juin Ting Chen
- Nidheesh Dadheech
- Adrian Kee Keong Teo